혈당 모니터링 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the blood glucose monitoring market size is projected to be USD 29.28 billion in 2025, USD 31.61 billion in 2026, and reach USD 51.26 billion by 2031, growing at a CAGR of 10.15% from 2026 to 2031.

This report is Segmented by Device (Self-Monitoring Blood Glucose [Glucometers, and More], and Continuous Glucose Monitoring), End User (Hospitals, and More), Patient Type (Type-1 Diabetes, and More), Distribution Channel (Institutional Sales, and More), and Geography (North America, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Blood Glucose Monitoring Market Trends and Insights

Accelerating Shift From Intermittent SMBG to Continuous & Connected Glucose Monitoring

CGM adoption is accelerating because early initiation lowers long-term hypoglycemia events and streamlines insulin titration protocols. Pediatric Type 1 cohorts in the United Kingdom reached 95% CGM uptake within 36 months of diagnosis by 2024, illustrating how national guidelines can redefine standard of care. Dexcom's 2024 direct integration with Apple Watch eliminates a separate receiver and delivers real-time alerts to 100 million users, embedding glucose insights into daily routines. Medicare's 2024 decision to reimburse CGM for insulin-using Type 2 patients widened the U.S. addressable base by 3.5 million beneficiaries. However, SMBG incumbents face commoditization: generic strips priced below USD 0.20 now dominate tenders in Brazil and India, eroding branded margins. The migration therefore rewards firms with sensor portfolios and data-driven service layers while punishing legacy strip pure-plays.

Rapid Expansion of Diabetes Prevalence and Earlier Screening in Emerging Economies

Global diabetes prevalence hit 828 million adults in 2024, quadrupling since 1990 and leaving 445 million undiagnosed. China's 140 million diagnosed cases and India's 101 million patients galvanize community-based screening and create demand for affordable monitoring solutions. The Indian Council of Medical Research's 2024 guidelines now advise glucose testing for all adults over 30 with one metabolic risk factor, bringing millions into the monitored population. Gulf Cooperation Council states show the world's highest age-adjusted prevalence and are digitizing registries to track adherence, bolstering CGM volumes despite oil-linked budget swings. Still, affordability gaps persist: a Brazilian cost-effectiveness study found that FreeStyle Libre reduced severe hypoglycemia by 43% but cost more than annual per-capita health spending in 18 of 27 states.

Persisting Affordability Gap for CGM Devices in Low-Income Segments

CGM systems typically cost USD 1,200-3,000 annually, well above median household incomes in India, Brazil, and much of Africa. Brazil's Unified Health System pays only for strips, leaving Libre adoption to private-pay elites despite a 43% reduction in severe hypoglycemia demonstrated in a 2023 study. India's public hospitals stock sensors in fewer than 2% of facilities, limiting access despite updated ICMR guidelines that endorse CGM for high-risk patients. China caps reimbursement at 50%, and rural uptake lags urban centers. Abbott introduced a lower-cost 10-day Libre at USD 30 in India in 2024, yet demand remains concentrated in metropolitan private clinics. These economics sustain SMBG strip demand priced below USD 0.30 and lock many patients into fingerstick routines.

Other drivers and restraints analyzed in the detailed report include:

1. Miniaturization & Wearable Sensor Innovations Enhancing User Convenience
2. Integration of Glucose Data Into Digital Therapeutics & Remote Patient Monitoring
3. Competitive Price Compression in SMBG Consumables From Generic Strip Proliferation

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

SMBG accounted for 53.01% of the blood glucose monitoring market in 2025, reflecting an installed base of more than 200 million glucometer users. However, CGM drives value creation; FreeStyle Libre 3 sensors retail for USD 70 per 14 days in the United States, and Dexcom G7 integrates directly with Apple Watch, justifying premium pricing through ecosystem synergies. Intellectual property now centers on algorithms, adhesives, and miniaturized electronics rather than strip chemistry, further tilting R&D budgets to CGM.

CGM's 15.09% forecast CAGR raises its slice of blood glucose monitoring market size each year, while SMBG revenues flatten under generic pressure. Transmitters are disappearing as smartphone displays absorb that function, lowering hardware bills yet boosting app stickiness. Integrated pump-CGM loops like Medtronic's MiniMed 780G automate insulin every five minutes and widen clinical distance from fingerstick-driven titration. Pre-commercial non-invasive prototypes garner venture funding but face an uncertain timeline to displace invasive incumbents entrenched behind strong reimbursement walls.

Hospitals and clinics held 31.45% revenue share in 2025 thanks to point-of-care testing mandates, but home-care settings held 59.10% revenue share and will post a 11.21% CAGR through 2031 as remote monitoring codes accelerate connected device deployment. The shift elevates blood glucose monitoring market share for consumer-centric brands and platforms that provide logistics, onboarding, and virtual coaching.

Hybrid closed-loop systems distributed by the U.K.'s NHS are reducing clinic visits, reinforcing the behavioral shift toward at-home management. Diagnostic laboratories lose relevance as CGM makes quarterly A1c draws less critical. China's community health centers and India's telemedicine rules further decentralize monitoring, favoring vendors with direct-to-consumer logistics capacity and cloud dashboards.

Complete Report Scope:

• By Device
  • Self-Monitoring Blood Glucose
    • Glucometers
    • Test Strips
    • Lancets & Lancing Devices
  • Continuous Glucose Monitoring
    • Sensors
    • Transmitters & Receivers
• By End User
  • Hospitals & Clinics
  • Homecare Settings
  • Diagnostic Laboratories
• By Patient Type
  • Type-1 Diabetes
  • Type-2 Diabetes
  • Gestational & Other Types
• By Distribution Channel
  • Institutional Sales
  • Retail Pharmacies
  • Online Sales
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained 41.96% of global revenue in 2025 on the back of Medicare's CGM expansion and high private-insurance penetration. U.S. uptake is approaching saturation in Type 1 cohorts, so incremental growth hinges on wider Type 2 coverage and employer wellness programs. Canada added Libre for all Type 1 patients in 2024, boosting sensor volumes in Ontario, Alberta, and British Columbia. Mexico's 16% adult prevalence presents scale, yet affordability constrains CGM to private urban clinics.

Asia-Pacific is forecast to deliver a 12.75% CAGR, propelled by China's 140 million diagnosed cases and India's growing reimbursement pilots. China's reimbursement covers only half the sensor cost, limiting rural penetration but driving urban growth. Japan formalized intermittently scanned CGM codes in 2024, sparking rapid uptake among elderly Type 2 patients. Australia's Pharmaceutical Benefits Scheme now subsidizes CGM for intensive Type 2 regimens, trimming hospital days by 30%.

Europe shows mature penetration but keeps expanding as Germany funds CGM for insulin-intensive Type 2 cases and the United Kingdom mandates hybrid closed-loop systems. Prevalence in the Middle East is highest globally; Saudi Arabia's digital registry seeks to improve adherence and capture outcomes. Latin America faces affordability hurdles: Brazil procures generic strips at USD 0.18 and CGM penetration remains under 5% outside private urban hospitals.

1. Abbott Laboratories (Diabetes Care)
2. Acon Laboratories
3. Agamatrix Holdings
4. Arkray
5. Ascensia
6. Biolinq Incorporated
7. Bionime
8. Dexcom
9. Roche
10. Insulet
11. Lifescan
12. Medtronic
13. MicroPort Life Sciences
14. Nipro
15. Nova Biomedical
16. Rossmax
17. Senseonics Holdings
18. Sinocare
19. Tandem Diabetes Care
20. Trividia Health
21. WaveForm Technologies
22. Ypsomed

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Accelerating shift from intermittent SMBG to continuous & connected glucose monitoring
  • 4.2.2 Rapid expansion of diabetes prevalence and earlier screening in emerging economies
  • 4.2.3 Miniaturization & wearable sensor innovations enhancing user convenience
  • 4.2.4 Integration of glucose data into digital therapeutics & remote patient monitoring
  • 4.2.5 Strategic pharma-med-tech-big-tech collaborations for end-to-end platforms
  • 4.2.6 Multi-payer alignment toward outcomes-based reimbursement
• 4.3 Market Restraints
  • 4.3.1 Persisting affordability gap for CGM devices in low-income segments
  • 4.3.2 Competitive price compression in SMBG consumables from generic strip proliferation
  • 4.3.3 Interoperability & cyber-security concerns hindering device-app data exchange
  • 4.3.4 Stringent evidence requirements for factory-calibrated non-invasive sensors
• 4.4 Supply-Chain Analysis
• 4.5 Reimbursement Outlook
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Device
  • 5.1.1 Self-Monitoring Blood Glucose
    • 5.1.1.1 Glucometers
    • 5.1.1.2 Test Strips
    • 5.1.1.3 Lancets & Lancing Devices
  • 5.1.2 Continuous Glucose Monitoring
    • 5.1.2.1 Sensors
    • 5.1.2.2 Transmitters & Receivers
• 5.2 By End User
  • 5.2.1 Hospitals & Clinics
  • 5.2.2 Homecare Settings
  • 5.2.3 Diagnostic Laboratories
• 5.3 By Patient Type
  • 5.3.1 Type-1 Diabetes
  • 5.3.2 Type-2 Diabetes
  • 5.3.3 Gestational & Other Types
• 5.4 By Distribution Channel
  • 5.4.1 Institutional Sales
  • 5.4.2 Retail Pharmacies
  • 5.4.3 Online Sales
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products & Services, and Recent Developments)
  • 6.3.1 Abbott Laboratories (Diabetes Care)
  • 6.3.2 ACON Laboratories Inc.
  • 6.3.3 Agamatrix Holdings
  • 6.3.4 ARKRAY Inc.
  • 6.3.5 Ascensia Diabetes Care
  • 6.3.6 Biolinq Incorporated
  • 6.3.7 Bionime Corporation
  • 6.3.8 Dexcom Inc.
  • 6.3.9 F. Hoffmann-La Roche Ltd
  • 6.3.10 Insulet Corporation
  • 6.3.11 LifeScan Inc.
  • 6.3.12 Medtronic plc
  • 6.3.13 MicroPort Life Sciences
  • 6.3.14 Nipro Corporation
  • 6.3.15 Nova Biomedical
  • 6.3.16 Rossmax International Ltd
  • 6.3.17 Senseonics Holdings
  • 6.3.18 Sinocare Inc.
  • 6.3.19 Tandem Diabetes Care
  • 6.3.20 Trividia Health
  • 6.3.21 WaveForm Technologies
  • 6.3.22 Ypsomed Holding AG

7 Market Opportunities & Future Outlook

• 7.1 White-Space & Unmet-Need Assessment